• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.

作者信息

Selinger Christian P, Lenti Marco Vincenzo, De Silvestri Annalisa

机构信息

Department of Gastroenterology, Leeds Teaching Hospitals, Leeds, UK.

Department of Internal Medicine, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

出版信息

Aliment Pharmacol Ther. 2022 Apr;55(8):1070-1071. doi: 10.1111/apt.16896.

DOI:10.1111/apt.16896
PMID:35362123
Abstract
摘要

相似文献

1
Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.信件：优特克单抗与维多珠单抗作为克罗恩病二线治疗药物的真实世界比较中的潜在选择偏倚——作者回复
Aliment Pharmacol Ther. 2022 Apr;55(8):1070-1071. doi: 10.1111/apt.16896.
2
Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.信函：乌司奴单抗与维多珠单抗作为克罗恩病二线治疗的真实世界比较中的潜在选择偏倚
Aliment Pharmacol Ther. 2022 Apr;55(8):1069. doi: 10.1111/apt.16871.
3
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
Aliment Pharmacol Ther. 2020 Oct;52(7):1255-1256. doi: 10.1111/apt.16062.
4
Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
Aliment Pharmacol Ther. 2020 Aug;52(4):753-754. doi: 10.1111/apt.15959.
5
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.乌司奴单抗相较于维得利珠单抗在既往抗 TNF 治疗失败的克罗恩病患者中具有更优的有效性结局。
Aliment Pharmacol Ther. 2020 Jul;52(1):123-134. doi: 10.1111/apt.15745. Epub 2020 May 22.
6
Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.维多珠单抗与优特克单抗联合治疗难治性克罗恩病的疗效
Inflamm Bowel Dis. 2017 Oct;23(10):E49. doi: 10.1097/MIB.0000000000001232.
7
The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.抗 TNF 药物和 vedolizumab 或 ustekinumab 均治疗无效的克罗恩病患者的结局。
Dig Liver Dis. 2020 Oct;52(10):1148-1155. doi: 10.1016/j.dld.2020.07.031. Epub 2020 Aug 20.
8
An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.优特克单抗与维多珠单抗治疗肿瘤坏死因子治疗失败的克罗恩病患者的间接比较
J Comp Eff Res. 2018 Feb;7(2):101-111. doi: 10.2217/cer-2017-0041. Epub 2017 Nov 8.
9
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.比较乌司奴单抗和维得利珠单抗治疗对肿瘤坏死因子治疗应答不佳的克罗恩病患者的短期和长期疗效。
Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299. doi: 10.1111/apt.16377. Epub 2021 Apr 28.
10
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.130 例抗 TNF 治疗失败的克罗恩病患者中乌司奴单抗或维得利珠单抗治疗 1 年后的疗效比较。
Aliment Pharmacol Ther. 2020 Oct;52(8):1341-1352. doi: 10.1111/apt.16057. Epub 2020 Sep 10.